Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Nvidia Options Price in $280 Billion Earnings Swing 
Add as a preferred source on Google
First Quarter 2018 Financial Results to be Announced May 8, 2018
Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials
CAMBRIDGE, Mass., May 01, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report the company’s first quarter 2018 financial results on Tuesday, May 8, 2018.
Epizyme also plans to host a conference call and webcast for investors on the morning of May 17, 2018 to discuss recent corporate updates and new tazemetostat clinical data that will be included in upcoming medical meeting abstracts. Details for this call will be provided in the company’s May 8 press release.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Contacts
Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561
Investors:
Jason Fredette, Epizyme, Inc.
[email protected]
(617) 500-0623
